Nanomedicine 2013

Check out our 2for1 offer!

Welcome to Nanomedicine 2013 conference and exhibition. 

Market researchers have estimated that the Nanomedicine industry was worth over $72.8 billion in 2011 and is expected to grow rapidly to the level of influencing entire economies. Due to major advances in science and engineering, the relatively young field of nanotechnology has been expanding significantly. Despite the exciting advancements in this discipline, which involves miniscule manufactured products 1 – 100nm in size, the field of nanomedicine has yet to be exploited to its full potential. A large part of the nanomedicine industry is within the use of nanoparticles for the treatment of cancerous tumors. However, many nanoparticles show signs of toxicity in cells and this can be caused by the inherent properties, size and surface charge of the particles. This leaves the door open for engineered solutions to enable nanomedicine to continue progressing at its historic rate.

This conference will aim to provide a multidisciplinary approach to tackle the fundamental challenges in this speciality, innovative strategies for testing exposure, and techniques for improving the reliability and accuracy of results. 

The conference will be co-located with our ADME & Predictive Toxicology meeting. Registered delegates will have unrestricited access to both meetings ensuring a comprehensive learning and sharing experience as well as being financially beneficial for attendees.

Keynote Speakers

Nadia Benkirane-Jessel Research Director, French National Institute of Health and Medical Research (Inserm)

Kattesh Katti Director, University of Missouri

Frederic Lagarce Professor of Pharmaceutical Technology & Biopharmaceutics, Inserm, LUNAM University

Gunter Oberdorster Professor, University of Rochester